Marksans Pharma Q1 FY27 Results (NSE: MARKSANS)
Signal: Margin expansion
The read
The key inflection is the return to strong margin expansion after Q1FY26 and Q2FY26 compression: consolidated EBITDA margin reached 25.3%, +919bps YoY and +251bps QoQ, with raw-material intensity down 483bps YoY and depreciation growing only 7.6%; however, consolidated revenue fell 1.8% QoQ and PAT included ₹254.04 million of other income, including a ₹120.01 million foreign-exchange gain.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹840.8 Cr | +35.6% | -1.8% |
| EBIT | ₹188.17 Cr | +144.3% | |
| Net profit | ₹159.41 Cr | +173.9% | |
| EPS | ₹3.47 | +169.0% | |
| EBIT margin | 25.3% |
P&L walk
Consolidated revenue rose to ₹8,407.96 million, +35.6% YoY but -1.8% QoQ; lower raw-material intensity and much stronger operating absorption lifted EBITDA to ₹2,130.35 million, +112.8% YoY, while PAT of ₹1,594.07 million, +173.9% YoY, also benefited from a lower effective tax rate and a ₹254.04 million other-income contribution.
Segments
The group-versus-parent gap is material: consolidated revenue was ₹8,407.96 million versus standalone revenue of ₹3,211.87 million, while consolidated PAT of ₹1,594.07 million was 2.3 times standalone PAT of ₹690.37 million, confirming that overseas subsidiaries remain the main earnings engine.
Key positives
- Consolidated revenue of ₹8,407.96 million grew +35.6% YoY, accelerating from +20.9% in Q4FY26 despite a -1.8% QoQ decline.
- EBITDA grew +112.8% YoY versus revenue +35.6%, a +77.2pp growth gap, with EBITDA margin expanding +919bps to 25.3%. Depreciation grew only +7.6% and finance costs +15.5% YoY.
- Gross margin expanded +1,791bps YoY to 59.2% as raw-material cost declined to 26.3% of revenue from 31.1%.
- PAT of ₹1,594.07 million rose +173.9% YoY and EPS of ₹3.47 rose +169.0%, with EPS tracking attributable profit cleanly.
- Acquisition of QliniQ B.V. for EUR 7.50 Million adds Dutch prescription-medicine and medical-device distribution capability; ABCnow GmbH was subsequently acquired for EUR 1.10 Million to strengthen German front-end distribution.
Key concerns
- Consolidated revenue declined 1.8% QoQ to ₹8,407.96 million, while standalone revenue fell 11.2% QoQ to ₹3,211.87 million, showing weaker sequential momentum at the parent level.
- Other income of ₹254.04 million was 12.3% of consolidated PBT and included a ₹120.01 million foreign-exchange gain, making the PAT comparison less purely operational.
- The filing states that financial information for seven subsidiaries was not reviewed by their auditors; the consolidated conclusion relies on management-prepared interim information for those entities.
- Employee benefits expense rose 29.3% YoY to ₹1,142.94 million, only moderately below revenue growth, so the margin expansion is not explained by broad-based employee-cost leverage alone.
Research and educational content only. Not investment advice.